The scarce asset is ownership of exception-heavy workflows where administrative burden, clinical ambiguity, reimbursement friction, and safety accountability intersect. A modest AI company embedded deeply into prior authorisation, post-acute coordination, or payer-clinician documentation may be more valuable than a technically impressive company floating above workflow reality.
